Innovative Diagnostics Paradigm Diagnostics offers a cutting-edge next-generation sequencing assay for personalized cancer treatment, presenting a compelling opportunity to target oncology clinics, hospital labs, and research institutions focused on precision medicine.

Growing Funding Base With a total funding of 10 million dollars and recent financing rounds, Paradigm is positioned for expansion and product development, making it suitable for investors seeking innovative biotech ventures in the early stage.

Regulatory Approvals The recent IRB approval for their Paradigm registry enables data sharing and visualization in oncology, creating potential sales channels to healthcare providers interested in advanced clinical data management solutions.

Tech-Driven Approach Utilizing modern technology stacks and analytics tools, Paradigm is well-placed to collaborate with tech-savvy diagnostics companies or integrate their solutions into existing healthcare IT infrastructure.

Market Opportunity With a niche in personalized oncology diagnostics and a small-to-medium employee base, Paradigm offers a focused opportunity for strategic partnerships or sales tailored to targeted cancer diagnostic markets and early-stage biotech allies.